✦ LIBER ✦

Histochemical study of the enzymatic activity of human neoplasms. II. Histogenesis of renal cell carcinoma

✍ Scribed by Herbert Braunstein; James U. Adelman

Publisher: John Wiley and Sons
Year: 1966
Tongue: English
Weight: 808 KB
Volume: 19
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(196607)19:7<935::aid-cncr2820190706>3.0.co;2-d

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A histochemical study of the enzymatic a

A histochemical study of the enzymatic activity of human neoplasms. I. Evidence suggesting deficiency of a succinoxidase carrier

✍ Herbert Braunstein 📂 Article 📅 1962 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB

Modulation of human lymphoblastoid inter

Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study

✍ Bruno Neri; Carlo Fiorelli; Fausto Moroni; Giulio Nicita; Maria Cristina Paolett 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 3 views

A phase II study of subcutaneous recombi

A phase II study of subcutaneous recombinant human lnterleukjn-4 in metastatic renal cell carcinoma

✍ Walter M. Stadler; Mary Ellen Rybak; Nicholas J. Vogelzang 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 1 views

A histochemical study of the enzymatic a

A histochemical study of the enzymatic activity of lymph nodes. II. Further investigation of normal and hyperplastic lymph nodes

✍ Herbert Braunstein; David G. Freiman; William Thomas Jr.; Edward A. Gall 📂 Article 📅 1962 🏛 John Wiley and Sons 🌐 English ⚖ 886 KB

Phase II study of recombinant human inte

Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies

✍ RECOMBINANT HUMAN INTERFERON GAMMA (S-6810) RESEARCH GROUP ON RENAL CELL CARCINO 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB 👁 1 views

A phase II study of constant-infusion fl

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma

✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub